Seaport Res Ptn Issues Pessimistic Outlook for HIMS Earnings

Hims & Hers Health, Inc. (NYSE:HIMS) – Analysts at Seaport Res Ptn dropped their FY2025 EPS estimates for shares of Hims & Hers Health in a report issued on Tuesday, November 4th. Seaport Res Ptn analyst A. Kessler now anticipates that the company will post earnings of $0.46 per share for the year, down from their previous estimate of $0.56. The consensus estimate for Hims & Hers Health’s current full-year earnings is $0.29 per share. Seaport Res Ptn also issued estimates for Hims & Hers Health’s Q4 2025 earnings at $0.03 EPS, Q1 2026 earnings at $0.14 EPS, Q2 2026 earnings at $0.14 EPS and Q4 2026 earnings at $0.15 EPS.

Other research analysts have also issued reports about the stock. Zacks Research lowered shares of Hims & Hers Health from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 19th. Weiss Ratings reissued a “hold (c+)” rating on shares of Hims & Hers Health in a research note on Tuesday, October 14th. KeyCorp began coverage on shares of Hims & Hers Health in a research report on Tuesday, October 21st. They set a “sector weight” rating for the company. Canaccord Genuity Group reissued a “buy” rating and set a $68.00 target price on shares of Hims & Hers Health in a research note on Friday, September 12th. Finally, Wall Street Zen lowered shares of Hims & Hers Health from a “buy” rating to a “hold” rating in a research note on Monday, July 28th. Two analysts have rated the stock with a Buy rating, ten have given a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat.com, Hims & Hers Health presently has a consensus rating of “Reduce” and an average target price of $45.27.

Hims & Hers Health Stock Up 2.2%

Shares of HIMS stock opened at $43.75 on Thursday. The company has a current ratio of 1.88, a quick ratio of 4.46 and a debt-to-equity ratio of 1.67. Hims & Hers Health has a 1 year low of $19.15 and a 1 year high of $72.98. The firm’s fifty day moving average price is $51.35 and its two-hundred day moving average price is $50.79. The firm has a market capitalization of $9.89 billion, a P/E ratio of 81.02, a PEG ratio of 3.09 and a beta of 2.20.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings results on Monday, November 3rd. The company reported $0.09 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.09. Hims & Hers Health had a net margin of 6.05% and a return on equity of 25.85%. The firm had revenue of $598.98 million for the quarter, compared to analyst estimates of $578.99 million. During the same period in the previous year, the business earned $0.32 EPS. The company’s revenue was up 49.2% compared to the same quarter last year. Hims & Hers Health has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS.

Hedge Funds Weigh In On Hims & Hers Health

Several hedge funds have recently bought and sold shares of the company. Oppenheimer & Co. Inc. grew its stake in Hims & Hers Health by 51.6% during the third quarter. Oppenheimer & Co. Inc. now owns 44,702 shares of the company’s stock valued at $2,535,000 after acquiring an additional 15,219 shares in the last quarter. Western Wealth Management LLC purchased a new position in Hims & Hers Health during the third quarter valued at approximately $242,000. Candriam S.C.A. grew its stake in Hims & Hers Health by 245.0% during the third quarter. Candriam S.C.A. now owns 306,273 shares of the company’s stock valued at $17,372,000 after acquiring an additional 217,493 shares in the last quarter. Smartleaf Asset Management LLC grew its stake in Hims & Hers Health by 44.7% during the third quarter. Smartleaf Asset Management LLC now owns 916 shares of the company’s stock valued at $54,000 after acquiring an additional 283 shares in the last quarter. Finally, Renaissance Group LLC grew its stake in Hims & Hers Health by 5.4% in the 3rd quarter. Renaissance Group LLC now owns 185,972 shares of the company’s stock worth $10,548,000 after buying an additional 9,588 shares in the last quarter. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Insider Activity at Hims & Hers Health

In other news, insider Irene Becklund sold 8,410 shares of the business’s stock in a transaction that occurred on Wednesday, September 17th. The shares were sold at an average price of $50.50, for a total value of $424,705.00. Following the sale, the insider owned 1,418 shares of the company’s stock, valued at $71,609. The trade was a 85.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Oluyemi Okupe sold 11,592 shares of the business’s stock in a transaction that occurred on Friday, October 17th. The shares were sold at an average price of $57.13, for a total transaction of $662,250.96. Following the completion of the sale, the chief financial officer directly owned 70,232 shares in the company, valued at approximately $4,012,354.16. This trade represents a 14.17% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 712,271 shares of company stock worth $37,631,985. Insiders own 13.71% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.